In this cross-sectional study of adults hospitalized with respiratory syncytial virus (RSV) before the 2023 introduction of RSV vaccines, RSV was associated with substantial burden of hospitalizations ...

In addition, annual estimates of RSV-associated ICU admissions ranged from 24,400 to 34,900 for the 2016-2017 and 2017-2018 ...

The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical ...

Compared with older adults hospitalized with influenza B, those hospitalized with respiratory syncytial virus (RSV) infection have a greater risk of dying within 90 days, according to a study ...

A genomic test developed by researchers to rapidly detect almost any kind of pathogen -- virus, bacteria, fungus or parasite -- has proved successful after a decade of use.

Infants are among the most susceptible to respiratory complications from respiratory syncytial virus ... antibody in animal ...

The seasonal COVID-19 spike, combined with rising cases of seasonal flu and RSV, brings what has been called a “tripledemic.” ...

COVID-19 spreads from an infected person to others through respiratory droplets and aerosols ... People with COVID-19 can spread the virus to animals during close contact. To prevent possible ...